To introduce the Via360 surgical system, a new device for glaucoma surgery that combines canaloplasty and trabeculotomy, enhancing surgical precision and patient outcomes through controlled viscodilation.
Approach:
Key Findings:
The Via360 system received FDA clearance in February 2025.
Surgeons report improved control and efficiency during procedures, with specific metrics indicating enhanced outcomes.
The device has shown promise in reducing IOP and medication burden in specific patient subgroups, supported by clinical data.
Interpretation:
The Via360 system enhances the capabilities of minimally invasive glaucoma surgery (MIGS) by allowing for customizable treatment options and improved surgical efficiency.
Limitations:
Potential for catheter misplacement into unintended areas; training and practice can mitigate this risk.
Requires training for optimal use despite its streamlined design; ongoing support and resources can enhance user proficiency.
Conclusion:
The Via360 system represents a significant advancement in MIGS, potentially reducing the need for more invasive surgeries and improving patient outcomes, particularly in those with complex glaucoma cases.
